Oculis Holding AG
OCS evidence brief
What we can confirm
- Market Cap:
- $636.9M
What it means
What to watch
Prepared research question
What matters most for OCS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · OCS
Oculis Holding AG is a global late clinical-stage biopharmaceutical company headquartered in Switzerland, focused on developing innovative therapeutics for neuro-ophthalmic and ophthalmic diseases with significant unmet medical needs [sec · filed 2026-03-04].
Key risk: No revenue history
Market Cap
$636.9M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Oculis Holding AG is a global late clinical-stage biopharmaceutical company headquartered in Switzerland, focused on developing innovative therapeutics for neuro-ophthalmic and ophthalmic diseases with significant unmet medical needs [sec · filed 2026-03-04].
- Oculis is a late clinical-stage biopharmaceutical company with operations in Switzerland, the U.S., and Iceland, focusing on neuro-ophthalmic and ophthalmic diseases [sec · filed 2026-03-04].
- Since inception through December 31, 2025, the company has raised approximately CHF 493.6 million from leading life science investors [sec · filed 2026-03-04].
- The company has never generated any revenue from product sales and has incurred significant net losses in each period since inception, with expectations of continued losses [sec · filed 2026-03-04].
- Key product candidates include OCS-01 for DME, Licaminlimab for DED, and Privosegtor (OCS-05) for neuro-ophthalmology indications, with a registrational program for Privosegtor initiated [sec · filed 2026-03-04][sec · filed 2025-10-06].
- The PIONEER program for Privosegtor includes three trials: PIONEER-1 expected to initiate in Q4 2025, PIONEER-2 in H1 2026, and PIONEER-3 evaluating NAION [sec · filed 2025-10-06].
What works
- Oculis has raised substantial capital (CHF 493.6 million as of December 31, 2025) from leading global investors, indicating strong financial backing for its development programs [sec · filed 2026-03-04].
- The company has an experienced management team with a track record of advancing drug candidates through regulatory approval and successful commercialization [sec · filed 2025-03-11].
- Privosegtor has received FDA guidance allowing evaluation in multiple neuro-ophthalmology indications under the current IND, and the PIONEER program is designed for potential operational synergies and accelerated development [sec · filed 2025-10-06].
What to weigh
- Oculis has never generated any revenue from product sales and has incurred significant net losses since inception, with expectations of continued increasing losses for the foreseeable future [sec · filed 2026-03-04].
- The company's success depends entirely on the development, regulatory approval, and commercialization of its three product candidates (OCS-01, Licaminlimab, Privosegtor), which are subject to high uncertainty and risk [sec · filed 2026-03-04].
- If additional financing is not obtained, the company may be unable to complete development and commercialization of its product candidates [sec · filed 2026-03-04].
- The company has not yet received any marketing approvals or commercialized any pharmaceutical products, making it difficult to evaluate its future viability [sec · filed 2026-03-04].
From the filings
Quoted directly from source documents.
Oculis is a late clinical-stage biopharmaceutical company focused on neuro-ophthalmic and ophthalmic diseases.
“We are a global late clinical-stage biopharmaceutical company, headquartered in Switzerland with operations in Switzerland, the U.S. and Iceland. We have substantial expertise in therapeutics for the treatment of neuro-ophthalmic and ophthalmic diseases.”
SEC filings · March 4, 2026
The company has raised CHF 493.6 million from investors through December 31, 2025.
“Since our inception through December 31, 2025, we have raised approximately CHF 493.6 million from leading North American, European and Asian life science investors.”
SEC filings · March 4, 2026
Oculis has never generated revenue from product sales and expects continued net losses.
“We have never generated any revenue from product sales, and we may never generate revenue or be profitable.”
SEC filings · March 4, 2026
Risks & what to watch (4)›
Key risks
- No revenue history — Oculis has never generated revenue from product sales and may never do so, with significant net losses continuing [sec · filed 2026-03-04].
- Dependence on few candidates
- Financing risk — Without additional financing, the company may be unable to complete development and commercialization [sec · filed 2026-03-04].
- No marketing approvals — No pharmaceutical products have been approved or commercialized, making future viability hard to assess [sec · filed 2026-03-04].
What to watch
- Initiation of PIONEER-1 trial for Privosegtor expected in Q4 2025 [sec · filed 2025-10-06].
- Initiation of PIONEER-2 trial for Privosegtor planned in H1 2026 [sec · filed 2025-10-06].
- Progress of OCS-01 and Licaminlimab clinical and regulatory plans [sec · filed 2026-03-04].
- Company's ability to secure additional financing to sustain operations and development [sec · filed 2026-03-04].
Sources: SEC filings · Generated October 13, 2026 · How we verify sources →
Run Oculis Holding AG through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Oculis Holding AG facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
17
Total value held
$113.8M
| Holder | Shares | Value |
|---|---|---|
| gildi - lifeyrissjodur | 2,430,401 | $64.3M |
| saturn v capital management lp | 516,761 | $13.7M |
| perceptive advisors llc | 493,827 | $13.1M |
| folketrygdfondet | 319,556 | $8.5M |
| woodline partners lp | 201,200 | $5.3M |
| compagnie lombard odier scma | 105,455 | $2.8M |
| acuta capital partners, llc | 98,339 | $2.6M |
| y-intercept (hong kong) ltd | 29,197 | $776K |
| quadrature capital ltd | 25,482 | $678K |
| boothbay fund management, llc | 24,960 | $664K |
Showing top 10 of 17 institutional holders of Oculis Holding AG. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 0.9%
- Days to cover
- 2.1
- Shares short
- 428,702
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
OCS short interestFrequently asked questions
What is the AI investment thesis for Oculis Holding AG?
Oculis Holding AG is a global late clinical-stage biopharmaceutical company headquartered in Switzerland, focused on developing innovative therapeutics for neuro-ophthalmic and ophthalmic diseases with significant unmet medical needs [sec · filed 2026-03-04].
Who is the CEO of Oculis Holding AG?
Dr. Riad Sherif M.B.A., M.D. is the chief executive officer of Oculis Holding AG (OCS).
Where is Oculis Holding AG headquartered?
Oculis Holding AG (OCS) is headquartered in Zug, Switzerland.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.